Skip Navigation



eCAM Advance Access published online on January 30, 2006

eCAM, doi:10.1093/ecam/nek010
This Article
Right arrow Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
3/1/31    most recent
nek010v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Seya, T.
Right arrow Articles by Matsumoto, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seya, T.
Right arrow Articles by Matsumoto, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2006). Published by Oxford University Press. All rights reserved.
Received September 3, 2005
Accepted December 26, 2005

Review

Role of Toll-like Receptors in Adjuvant-Augmented Immune Therapies

Tsukasa Seya 1 *, Takashi Akazawa 2, Tadayuki Tsujita 3, and Misako Matsumoto 1

1 Department of Microbiology and Immunology, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku Sapporo 060-8638, Japan; Department of Immunogy, Osaka Medical Center for Cancer, Nakamichi 1-3-2, Higashinari-ku, Osaka 537-8511, Japan
2 Department of Immunogy, Osaka Medical Center for Cancer, Nakamichi 1-3-2, Higashinari-ku, Osaka 537-8511, Japan
3 Department of Microbiology and Immunology, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku Sapporo 060-8638, Japan; Present address: ERATO-JST, Laboratory of Molecular and Developmental Biology, University of Tsukuba, Tennoudai 1-1-1, Tsukuba 305-8577, Japan

* To whom correspondence should be addressed.
Tsukasa Seya, E-mail: seya-tu{at}med.hokudai.ac.jp


   Abstract

Effective therapeutic vaccines contain two primary constituents, antigen and adjuvant. Adjuvants consisting of microbial pattern molecules play a central role in vaccination. Successful vaccine requires efficient induction of antibody (Ab), type I interferons (IFN), cytokines/chemokines, cytotoxic T lymphocytes (CTL) and/or NK cells. Toll-like receptors (TLRs) in myeloid dendritic cells (mDC) essentially act as adjuvant receptors and sustain the molecular basis of adjuvant activity. Current consensus is that TLRs and their adapters introduce signals to preferentially induce IFN-{alpha}/{beta}, chemokines and proinflammatory cytokines, and mature mDC to augment antigen presentation. Although most of these data were obtained with mice, the results are presumed to be adaptable to humans. Whenever TLR pathway is activated in mDC, NK and/or CTL activation is promoted. For induction of antigen-specific CTL toward phagocytosed material, cross-priming must be induced in mDC, which is also sustained by TLR signaling in mDC. Since the TLR responses vary with different adjuvants, mDC functions are skewed depending on adjuvant-specific direction of mDC maturation. It appears that the directed maturation of mDC largely relies on selection of appropriate sets of TLRs and their adapter signaling pathways. Synthetic chimera molecules consisting of TLR agonists and target antigens are found to be effective in induction of CTL to eliminate target cells in vivo. Here, we review the role of human TLRs and adapters in a variety of host immune responses. We will also describe the relevance of adjuvants in the manipulation of receptors and adapters in vaccine therapy.

Keywords: adjuvants; dendritic cells; interferon; microbial pattern molecules; Toll-like receptor.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Gen. Virol.Home page
L. M. Pletneva, O. Haller, D. D. Porter, G. A. Prince, and J. C. G. Blanco
Induction of type I interferons and interferon-inducible Mx genes during respiratory syncytial virus infection and reinfection in cotton rats
J. Gen. Virol., January 1, 2008; 89(1): 261 - 270.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
H. Izadi, A. T. Motameni, T. C. Bates, E. R. Olivera, V. Villar-Suarez, I. Joshi, R. Garg, B. A. Osborne, R. J. Davis, M. Rincon, et al.
c-Jun N-Terminal Kinase 1 Is Required for Toll-Like Receptor 1 Gene Expression in Macrophages
Infect. Immun., October 1, 2007; 75(10): 5027 - 5034.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
P. Hubert, N. Jacobs, J.-H. Caberg, J. Boniver, and P. Delvenne
The cross-talk between dendritic and regulatory T cells: good or evil?
J. Leukoc. Biol., October 1, 2007; 82(4): 781 - 794.
[Abstract] [Full Text] [PDF]


Home page
Evid Based Complement Alternat MedHome page
E. L. Cooper
Role of TOLL-like Receptors in Adjuvant-Augmented Immune Therapies by T. Seya.
Evid. Based Complement. Altern. Med., March 1, 2006; 3(1): 133 - 137.
[Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.